Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility Equipment is expected to be installed and ready for first harvest later this year
SEATTLE, April 24, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced arrival of the first shipment of factory equipment to its production facility in South Africa. The processing line will be used in the Company's proprietary extraction process, which produces botanicals with a higher degree of bioavailability than other botanical phytonutrients on the market.
Installation, calibration and testing of the equipment is expected by August with the processing and extraction facility expected to be ready for the first harvest in November 2013.
"Shipment of this equipment is an important first step in the ramping up of production at our production facility in South Africa," said Roger Duffield, Chairman and Chief Executive Officer of Plandai Biotechnology. "With distribution agreements already in place, we are looking forward to increased production as levels of tea leaf harvesting increases."
Plandai Biotechnology, through its wholly owned subsidiaries, farms over 7,500 acres of luscious land in the Mpumalanga province of South Africa. The Company is currently farming 1,000 acres of tea bushes, increasing to 2,200 acres over the next five years.
In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today. Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.
The Company believes that its technology is the foundation for creating an entirely new family of botanical drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
SOURCE Plandai Biotechnology, Inc.